Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 14/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 14/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 14/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.54 |
| ▸ | CFB | P00751 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369306 | 0.74 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CADRA1ACFB | |
| SCHEMBL1723548 | 0.72 | ADRA2B (0.84) | ADRA2AADRA2BADRA2CADRA1ABCHE | |
| SCHEMBL2215859 | 0.72 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CADRA1ACFB | |
| SCHEMBL3751385 | 0.71 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CADRA1ACFB | |
| SCHEMBL10554892 | 0.70 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1ACFB | |
| SCHEMBL10555827 | 0.70 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1ACFB | |
| SCHEMBL1724062 | 0.70 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ATSHR | |
| SCHEMBL10680232 | 0.70 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1ACFB | |
| SCHEMBL4054961 | 0.66 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CADRA1ATSHR | |
| SCHEMBL4564280 | 0.66 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706747-B2 | TREATING ELEVATED INTRAOCULAR PRESSURE, DEPRESSION, NON INSULIN-DEPENDENT DIABETES, MALE IMPOTENCE AND OBESITY WHICH IS ALLEVIATED BY TREATMENT WITH AN ALPHA 2 BLOCKING AGENT | ALLERGAN, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20030187047-A1 | Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents | ALLERGAN SALES, INC. | 2003-10-02 | — | — | US | disclosed |
| US-6569884-B2 | Trans-2-(3-phenyl-bicyclo(2.2.1)heptyl)-2-aminooxazoline, for example; treating intraocular pressure, noninsulin-dependent diabetes, male impotence and obesity | ALLERGAN | 2003-05-27 | — | — | US | disclosed |
| EP-0724439-B1 | USE OF 2-(2ALKYLPHENYLAMINO)OXAZOLINES AND -THIAZOLINES FOR THE MANUFACTURE OF A MEDICAMENT WITH ALPHA 2 ADRENERGIC EFFECT | ALLERGAN SALES INC (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020049241-A1 | Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents | ALLERGAN SALES, INC. | 2002-04-25 | — | — | US | disclosed |
| EP-0770068-B1 | CONFORMATIONALLY RIGID BICYCLIC AND ADAMANTANE DERIVATIVES USEFUL AS ALPHA 2-ADRENERGIC BLOCKING AGENTS | ALLERGAN SALES INC (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6319935-B1 | USED IN TREATMENT OF ELEVATED INTRAOCULAR PRESSURE, NON INSULIN-DEPENDENT DIABETES, MALE IMPOTENCE AND OBESITY | ALLERGAN SALES, INC. | 2001-11-20 | — | — | US | disclosed |
| US-6150389-A | ANTIDEPRESSANTS; TREATING ELEVATED INTRAOCULAR PRESSURE, E.G., GLAUCOMA; ANTIDIABETIC AGENTS FOR NON-INSULIN DEPENDENT DIABETES, SEXUAL DISORDERS, E.G., MALE IMPOTENCE AND OBESITY; E.G. TRANS-2-(3-PHENYL-BICYCLO(2.2.1)HEPTYL)-2-AMINOOXAZOLINE | ALLERGAN SALES, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-5731337-A | Conformationally rigid bicycle and adamantane derivatives useful as α2 | ALLERGAN (US) | 1998-03-24 | — | — | US | disclosed |
| US-5708015-A | SENSITIVE ALPHA 2 ADRENERGIC RECEPTORS | ALLERGAN (US) | 1998-01-13 | — | — | US | disclosed |
| US-5580892-A | ANTIDIARRHETIC, ANTISPASTIC, ANTIEPILEPTIC AGENTS; DIURETICS | ALLERGAN | 1996-12-03 | — | — | US | disclosed |
| EP-0724439-A1 | USE OF 2-(2-ALKYLPHENYLAMINO)-OXAZOLINES, -THIAZOLINES AND -IMIDAZOLINES AS ALPHA 2 ADRENERGIC AGENTS | Allergan (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995011021-A1 | USE OF 2-(2-ALKYLPHENYLAMINO)-OXAZOLINES, -THIAZOLINES AND -IMIDAZOLINES AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN (US) | 1995-04-27 | — | — | WO | disclosed |
| US-5252595-A | Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines | ALLERGAN, INC. (US) | 1993-10-12 | — | — | US | disclosed |
| US-5151440-A | Treatment of glaucoma | ALLERGAN, INC. (US) | 1992-09-29 | — | — | US | disclosed |
| US-5066664-A | Control of intraocular bleeding and pressure | ALLERGAN, INC. (US) | 1991-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049241-A1 | Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents | ADRB2, ADRB1, ADRA1B | ADRA2A 8/4885ADRA2B 9/4885ADRA2C 7/4885 |
| US-20030187047-A1 | Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents | ADRB2, ADRB1, ADRA1B | ADRA2A 8/4885ADRA2B 9/4885ADRA2C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.